IndraLab
Statements
Vorinostat inhibits mutated TP53. 11 / 11
|
11
reach
"A combined approach using ulixertinib (ERK inhibitor) with vorinostat (HDAC inhibitor) and tanespimycin (HSP90 inhibitor) [38, 39], which all have been reported to cross the blood-brain barrier, could potentially degrade the mutant p53 protein, and target STK11-mutant cells by abolishing S6 protein."
reach
"Specifically, suberoylanilide hydroxamic acid (SAHA, also known as vorinostat), a FDA approved HDACi that inhibits class I, II, and IV HDACs, induces degradation of mutant p53 by inhibiting HDAC6 activity, an essential positive regulator of Hsp90, and subsequent disruption of the HDAC6/Hsp90/mutant p53 complex, leading to mutant p53 ubiquitination by MDM2 and CHIP."
reach
"Taken together these findings indicated that SAHA combined with PENAO synergistically reduced mutant p53 protein stability, potentially triggering apoptotic cell death.3.9
SAHA combined with PENAO significantly delays tumour growth and induces apoptosis in
TP53
mutant NB xenograft models."